TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
OrbusNeich Medical Group Holdings Limited
Press Release
OrbusNeich Records Net Profit of US$18.8 Million for the First Half of 2024
Aug 16, 2024 20:47 JST
OrbusNeich Medical Group Holdings Limited ('OrbusNeich' or the 'Group'; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention ('PCI') and percutaneous transluminal angioplasty ('PTA') procedures, today announced its interim results for the six months ended June 30, 2024 (the 'Reporting Period), with revenue and profit for the period attributable to owners of the Company maintained at US$78.9 million and US$18.8 million respectively despite various market challenges.
More info..
OrbusNeich's Joint Venture Kicks Off TricValve Clinical Trial in Mainland China
Apr 24, 2024 18:59 JST
OrbusNeich Medical Group Holdings Limited announced today that the Group's joint venture OrbusNeich P+F Company Limited ("ON P&F") has commenced the clinical trial for the TricValve Transcatheter Bicaval Valve System ("TricValve"), to treat patients with hemodynamically relevant tricuspid insufficiency and caval reflux, on April 22, 2024 across Mainland China.
More info..
OrbusNeich Achieves Record-High Revenue and Net Profit of US$154 Million and US$45.1 Million Respectively, Recommends Final Dividend Payment of HK10 cents per Share
Mar 07, 2024 17:20 JST
OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures
More info..
OrbusNeich Acquires 84% Stake in Indonesian Distributor PT Revass for Approximately US$15 Million
Nov 27, 2023 09:00 JST
OrbusNeich Medical Group Holdings Limited ("OrbusNeich", 6929.HK), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures
More info..
OrbusNeich Adds Drug-eluting Balloons in Product Portfolio Through Acquisition of Eucatech AG
Nov 23, 2023 09:15 JST
OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures
More info..
OrbusNeich FY2023 Interim Net Profit Triples to US$25.2 Million, Total Revenue Increases by 18.2% to US$81.4 Million
Aug 17, 2023 17:52 JST
OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, today announced its interim results for the six months ended 30 June 2023, reporting growth in both revenue and net profit.
More info..
OrbusNeich Kicks Off Clinical Study of Scoreflex TRIO, Completing China's First PCI Intervention Procedure with High-Pressure, Three-wire Scoring Balloon Dilatation Catheter
May 08, 2023 17:58 JST
OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures
More info..
OrbusNeich Plans to Set up Its Largest R&D and Production Base in Fuchun Bay New Town, Hangzhou, the PRC
Mar 28, 2023 17:28 JST
OrbusNeich Medical (Zhejiang) Company Limited ("OrbusNeich Zhejiang"), a wholly-owned subsidiary of OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures
More info..
OrbusNeich Announces First Annual Results After Listing, Record Revenue of US$136.8 Million, Adjusted Net Profit Up 25% to US$26.7 Million
Mar 08, 2023 18:00 JST
OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures
More info..
Shares of Major Global Medical Device Manufacturer OrbusNeich Medical Group Commence Trading on the Main Board of The Stock Exchange of Hong Kong
Dec 23, 2022 15:10 JST
Shares of OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"), a major global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, today commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("HKEX"), under the stock code 6929.
More info..
Major Global Medical Device Manufacturer OrbusNeich Medical Group Announces Details of Proposed Listing on the Main Board of HKEX
Dec 13, 2022 10:10 JST
OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"), a major global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, has today announced the details of its proposed listing on the Main Board of The Stock Exchange of Hong Kong Limited ("HKEX").
More info..
1
Latest Release
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 months with Individualized Cancer Vaccine TG4050
Jun 02, 2025 17:56 JST
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan
Jun 02, 2025 17:46 JST
Mitsubishi Corporation to Invest and Enter into a Business Partnership with DEScycle Ltd., a UK Company Developing Innovative Metal Recycling Technology
Jun 02, 2025 14:35 JST
MyJCB App Wins Gold at A' Design Award & Competition
Jun 02, 2025 12:00 JST
Fujitsu Technology Park's redevelopment project launch
Jun 02, 2025 11:23 JST
Mitsubishi Corporation Establishes New Corporate Venture Capital Company
May 30, 2025 18:36 JST
Honda to Co-develop Refueling Port Connecting System for On-orbit Satellite Refueling with Astroscale
May 30, 2025 11:54 JST
IFS and NEC Strengthen their Strategic Partnership to Create New Value
May 30, 2025 10:11 JST
Mazda Production and Sales Results for April 2025
May 29, 2025 18:44 JST
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
May 28, 2025 17:45 JST
GK Software becomes a Fujitsu company
May 28, 2025 15:33 JST
Construction Begins on New Toyota Tokyo Head Office in Shinagawa, to Open in FY2030
May 27, 2025 14:31 JST
JCB partners with PayXpert to expand in-store card acceptance for international shoppers and travellers coming to Europe and in the UK
May 27, 2025 12:00 JST
JCB Collaborates with Noage International to Expand Advanced Medical Tourism Program in Japan for Affluent Indonesians
May 27, 2025 10:00 JST
Ministry of Energy of Uzbekistan and MHI Sign MOU to Conduct Joint Study of Decarbonization Strategy for Uzbekistan
May 27, 2025 09:49 JST
Fujitsu launches second corporate venture capital fund to drive innovation and achieve a sustainable society
May 26, 2025 18:27 JST
Fujitsu and Tokai National Higher Education and Research System utilize AI to accelerate clinical research and tackle 'drug loss' in Japan
May 23, 2025 17:29 JST
Lockheed Martin and Fujitsu Strengthen Japan Industry Collaboration with SPY-7 Supplier Selection and Strategic Agreements
May 23, 2025 13:36 JST
NIED, Fujitsu, SDS and Mitsubishi Electric sign joint research agreement to advance Japan Disaster Charter operational framework
May 23, 2025 13:35 JST
Honda Expands Production Capacity by Adding New Production Line at Fourth Motorcycle Plant in India
May 23, 2025 12:17 JST
More Latest Release >>